Cornerstone Capital Management Holdings LLC. raised its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 486.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,866 shares of the specialty pharmaceutical company’s stock after buying an additional 18,966 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in AMAG Pharmaceuticals were worth $515,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in AMAG. Bank of Montreal Can raised its stake in shares of AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the period. Comerica Bank raised its stake in shares of AMAG Pharmaceuticals by 5.1% in the fourth quarter. Comerica Bank now owns 36,399 shares of the specialty pharmaceutical company’s stock worth $837,000 after buying an additional 1,764 shares during the period. New York State Teachers Retirement System raised its stake in shares of AMAG Pharmaceuticals by 5.0% in the fourth quarter. New York State Teachers Retirement System now owns 25,325 shares of the specialty pharmaceutical company’s stock worth $881,000 after buying an additional 1,200 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of AMAG Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 406,303 shares of the specialty pharmaceutical company’s stock worth $14,140,000 after buying an additional 6,507 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $17,870,000.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 18.35 on Friday. AMAG Pharmaceuticals, Inc. has a 12 month low of $16.00 and a 12 month high of $36.83. The company has a 50-day moving average price of $18.26 and a 200-day moving average price of $23.88. The firm’s market capitalization is $643.08 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $1.15. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The firm had revenue of $139.47 million during the quarter, compared to analyst estimates of $150.32 million. During the same period in the previous year, the company earned ($0.22) EPS. AMAG Pharmaceuticals’s revenue for the quarter was up 27.6% on a year-over-year basis. Equities analysts forecast that AMAG Pharmaceuticals, Inc. will post $5.09 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/06/25/cornerstone-capital-management-holdings-llc-increases-position-in-amag-pharmaceuticals-inc-amag.html.

AMAG has been the subject of a number of research reports. Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, April 20th. Cantor Fitzgerald set a $24.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, February 27th. TheStreet lowered AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Barclays PLC reiterated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. Finally, ValuEngine lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. AMAG Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $29.44.

In other news, SVP Julie Krop sold 1,891 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $24.45, for a total value of $46,234.95. Following the completion of the sale, the senior vice president now owns 36,777 shares of the company’s stock, valued at $899,197.65. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 3.80% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.